Page last updated: 2024-11-01

ondansetron and Carcinoma

ondansetron has been researched along with Carcinoma in 2 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.

Research Excerpts

ExcerptRelevanceReference
"We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time."9.07Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991)
"We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time."5.07Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Verwimp-Hoeks, MPA1
van Herpen, CML1
Burger, DM1
Fraschini, G1
Ciociola, A1
Esparza, L1
Templeton, D1
Holmes, FA1
Walters, RS1
Hortobagyi, GN1

Trials

1 trial available for ondansetron and Carcinoma

ArticleYear
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:7

    Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1991

Other Studies

1 other study available for ondansetron and Carcinoma

ArticleYear
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Adult; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Carcinoma; Chemoradiot

2012